Honor Witness | Haibu Pharmaceutical Awarded 'ADC New Infrastructure Pioneer Enterprise'
Classification:
Company News
Release time:
2024-05-15
On April 18, the heavyweight brand conference - "The First Future XDC New Drug Conference" jointly created by Tongxieyi and Chengdu Medical City kicked off in Chengdu Medical City.
The conference focused on the theme of "Co-creating the Future of the Conjugated Drug Industry", concentrating on industrial research ecology and grasping the wave of technological change. Over 1,600 R&D experts, scholars, and production professionals from the industry provided authoritative technical interpretation perspectives and guidance for pharmaceutical innovators. Meanwhile, the online live broadcast attracted more than 20,000 viewers.
Xieyi Evening Party
"The Sky of Bioconjugation"
At the evening party, a list of pioneering companies in ADC/nuclear drug innovation was released, with Haibu Pharmaceutical awarded as an "ADC New Infrastructure Pioneer Company."
Haibu Pharmaceutical began its involvement in ADC small molecule R&D business in 2018. It currently has rich experience in Linker design, selection and design of Payloads, Linker-antibody conjugation, and DAR control. Clients with needs are welcome to contact for discussions.
Service hotline: 010-67887110-8088
Email: diwei@hopelife.cn
Beijing Haibu Pharmaceutical Technology Co., Ltd. (referred to as "Haibu Pharmaceutical") was established in 2005 and is a high-tech enterprise with "chemical drug R&D" as its core capability. It has a Beijing R&D center, an API and formulation pilot verification center, and a GMP industrial production base. The company mainly engages in CRO services for APIs and formulations, MAH joint licensing, API-related declarations, and commercial supply of pharmaceutical intermediates.It has rich experience in R&D transfer production and registration declaration for various dosage forms such as chemical APIs, oral solids, liquid formulations, sterile injections, and external preparations. The R&D products cover multiple indication areas including anti-tumor, anti-depression, anti-epilepsy, anti-anxiety, cardiovascular diseases, digestive system diseases, respiratory system diseases.
Haibu Pharmaceutical has been awarded the title of "Top 20 Chinese Pharmaceutical R&D Companies" for many years consecutively and recognized as a "Specialized & Innovative Enterprise" by Beijing Municipality; it is also designated as a "National High-tech Enterprise", "Beijing Science & Technology Research Development Institution", and "Beijing Yizhuang Enterprise Innovation Center", among others.
Beijing Hope Pharmaceutical Co., Ltd.
